Proton Radiation Therapy for Gliomas

Status Active, not recruiting

Clinical Trial Summary

In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study the investigators are looking to determine if proton radiation with a reduced field size will be as effective in controlling tumor growth as photon therapy, while reducing the treatment-related side effects observed in patients with brain tumors.

Clinical Trial Description

Proton radiation will be delivered daily for approximately 6 weeks. Subjects will be assessed weekly for side effects. Each visit will take about 15 minutes. Subjects will have follow-up visits at 3, 6, 12, 24, 36, 48, 60, 72, and 84 months after their last proton radiation treatment. They will receive a physical exam, MRI, have blood tests (about 4 teaspoons) and answer questionnaires regarding medical history, quality of life, and emotional well-being. Subjects will also receive a neurocognitive exam annually. ;

Study Design

Related Conditions & MeSH terms

Glioma
Low Grade Glioma
WHO Grade 3 Glioma With 1p/19q Codeletion
WHO Grade 3 Glioma With IDH1 Mutation

Clinical Trial Details

NCT number	NCT01358058
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	May 2011
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT04044937` - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms	Phase 2
Terminated	`NCT01452854` - Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
Recruiting	`NCT03952598` - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	N/A
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT05964569` - Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma	Phase 2
Completed	`NCT02607397` - ROCOCO - Low Grade Glioma - Planning Study	N/A
Recruiting	`NCT03718767` - Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype	Phase 2
Recruiting	`NCT02455245` - A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma	Phase 3
Completed	`NCT02186262` - Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
Terminated	`NCT02023905` - Everolimus With and Without Temozolomide in Adult Low Grade Glioma	Phase 2
Recruiting	`NCT01386450` - AZD6244 in Children With Low-Grade Gliomas	Phase 1/Phase 2
Completed	`NCT02286531` - Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma	N/A
Active, not recruiting	`NCT04553757` - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Not yet recruiting	`NCT06132685` - Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial	Phase 2
Recruiting	`NCT04166409` - A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma	Phase 3
Recruiting	`NCT02358187` - A Vaccine Trial for Low Grade Gliomas	Phase 2
Recruiting	`NCT03871257` - A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma	Phase 3
Terminated	`NCT01281982` - (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
Active, not recruiting	`NCT01288235` - Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation	Phase 2